市場調查報告書

肢端肥大症 - 市場洞察,流行病學,市場預測 ∼2027年

Acromegaly and Gigantism Therapeutics - Market Insight, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 602022
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
肢端肥大症 - 市場洞察,流行病學,市場預測 ∼2027年 Acromegaly and Gigantism Therapeutics - Market Insight, Epidemiology and Market Forecast - 2028
出版日期: 2019年01月01日內容資訊: 英文 100 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的肢端肥大症的總患病數2016年估計為6萬610人。

本報告提供肢端肥大症的相關調查,疾病概要,患者背景,主要7個國家肢端肥大症的患病數、診斷數的預測(今後10年份),已上市藥及新藥概要,市場成長要素、阻礙因素,市場機會,競爭情形等資訊。

目錄

第1章 重要的洞察

第2章 尖端巨大市場概要

  • 市場佔有率(最新值)肢端肥大症的分佈
  • 市場佔有率(預測值)肢端肥大症的分佈

第3章 疾病概要:肢端肥大症(ACM)

  • 簡介
  • 徵兆與症狀
  • 下垂體腺瘤的分類
  • 肢端肥大症臨床症狀
  • 病因
  • 病理生理學
  • 肢端肥大症的遺傳性根據
  • 病因
  • 診斷
    • 診斷指南
    • 內分泌學會診療指南作成委員(英國)
    • 美國臨床內分泌學會(美國)

第4章 流行病學和患者人口

第5章 主要觀察

第6章 主要7個國家的流行病學

  • 肢端肥大症的總患病數

第7章 美國的流行病學

  • 肢端肥大症的總患病數
  • 肢端肥大症的患病數:各原因
  • 肢端肥大症的診斷數
  • 肢端肥大症的診斷數:各腺瘤
  • 肢端肥大症的治療可能的病例數

第8章 歐盟5國的流行病學

  • 英國
    • 肢端肥大症的總患病數
    • 肢端肥大症的患病數:各原因
    • 肢端肥大症的診斷數
    • 肢端肥大症的診斷數:各腺瘤
    • 肢端肥大症的治療可能的病例數
  • 德國
    • 肢端肥大症的總患病數
    • 肢端肥大症的患病數:各原因
    • 肢端肥大症的診斷數
    • 肢端肥大症的診斷數:各腺瘤
    • 肢端肥大症的治療可能的病例數
  • 法國
    • 肢端肥大症的總患病數
    • 肢端肥大症的患病數:各原因
    • 肢端肥大症的診斷數
    • 肢端肥大症的診斷數:各腺瘤
    • 肢端肥大症的治療可能的病例數
  • 義大利
    • 肢端肥大症的總患病數
    • 肢端肥大症的患病數:各原因
    • 肢端肥大症的診斷數
    • 肢端肥大症的診斷數:各腺瘤
    • 肢端肥大症的治療可能的病例數
  • 西班牙
    • 肢端肥大症的總患病數
    • 肢端肥大症的患病數:各原因
    • 肢端肥大症的診斷數
    • 肢端肥大症的診斷數:各腺瘤
    • 肢端肥大症的治療可能的病例數

第9章 日本的流行病學

  • 肢端肥大症的總患病數
  • 肢端肥大症的患病數:各原因
  • 肢端肥大症的診斷數
  • 肢端肥大症的診斷數:各腺瘤
  • 肢端肥大症的治療可能的病例數

第10章 治療

  • 肢端肥大症的生物標記
  • 治療指南
    • 美國臨床內分泌學會(美國)
    • 內分泌學會診療指南作成委員(英國)

第11章 未滿足需求

第12章 上市藥

  • Somatuline Depot(醋酸蘭瑞肽):Ipsen Biopharmaceuticals
    • 醫藥品概要
    • 法規的里程碑
    • 優點與缺點
    • 安全性和有效性
    • 產品的簡介
  • Somavert (pegvisomant): Pharmacia & Upjohn
  • Sandostatin LAR Depot: Novartis Pharmaceuticals
  • Signifor LAR (pasireotide): Novartis Pharmaceuticals

第13章 競爭情形

第14章 新藥

  • IONIS-GHR-LRx:Ionis Pharmaceuticals
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 臨床試驗資訊
    • 安全性和有效性
    • 產品的簡介
  • Octreotide capsules: Chiasma Pharma
  • ATL1103: Antisense Therapeutics
  • CAM2029: Novartis
  • GT-02037: Pharmaspur
  • Veldoreotide: Evotec/ Aspireo Pharmaceuticals

第15章 分析肢端肥大症:主要7個國家

  • 主要的觀察
  • 主要7個國家的肢端肥大症的市場規模

第16章 美國市場預測

  • 市場規模
  • 整體市場規模
  • 市場規模:各治療藥物

第17章 歐盟5國的市場展望

  • 英國的市場規模
    • 市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 德國的市場規模
    • 市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國的市場規模
    • 市場規模
    • 整體市場規模
    • 市場規模:治療藥物別
  • 義大利的市場規模
    • 市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 西班牙的市場規模
    • 市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第18章 日本的市場展望

  • 日本的市場規模
    • 市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第19章 市場成長要素

第20章 市場阻礙因素

第21章 附錄

  • 調查手法

第22章 DelveInsight的服務內容

第23章 免責聲明

第24章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0240

DelveInsight's "Acromegaly and Gigantism Therapeutics - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Acromegaly and Gigantism Therapeutics epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Acromegaly and Gigantism Therapeutics Understanding and Treatment Algorithm

The market report provides the overview of the Acromegaly and Gigantism Therapeutics by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Acromegaly and Gigantism Therapeutics Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Acromegaly and Gigantism Therapeutics in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Acromegaly and Gigantism Therapeutics Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Acromegaly and Gigantism Therapeutics Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Acromegaly and Gigantism Therapeutics market.

Acromegaly and Gigantism Therapeutics Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Acromegaly and Gigantism Therapeutics Report Insights

  • Patient Population in Acromegaly and Gigantism Therapeutics
  • Therapeutic Approaches in Acromegaly and Gigantism Therapeutics
  • Acromegaly and Gigantism Therapeutics Pipeline Analysis
  • Acromegaly and Gigantism Therapeutics Market Size and Trends
  • Acromegaly and Gigantism Therapeutics Market Opportunities
  • Impact of upcoming Therapies in Acromegaly and Gigantism Therapeutics

Acromegaly and Gigantism Therapeutics Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Acromegaly and Gigantism Therapeutics Report Assessment

  • Current Treatment Practices in Acromegaly and Gigantism Therapeutics
  • Unmet Needs in Acromegaly and Gigantism Therapeutics
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Acromegaly and Gigantism Therapeutics market
  • Organize sales and marketing efforts by identifying the best opportunities for Acromegaly and Gigantism Therapeutics market
  • To understand the future market competition in the Acromegaly and Gigantism Therapeutics market.

Table of Contents

1. Report Introduction

2. Acromegaly and Gigantism Therapeutics Market Overview at a Glance

  • 2.1. Market Share Distribution of Acromegaly and Gigantism Therapeutics in 2016
  • 2.2. Market Share Distribution of Acromegaly and Gigantism Therapeutics in 2028

3. Disease Background and Overview: Acromegaly and Gigantism Therapeutics

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Acromegaly and Gigantism Therapeutics in 7MM
  • 4.3. Total Prevalent Patient Population of Acromegaly and Gigantism Therapeutics in 7MM - By Countries

5. Epidemiology of Acromegaly and Gigantism Therapeutics by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.1.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.1.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.1.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.1.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.4.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.4.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.4.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.4.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.5.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.5.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.5.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.5.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.6.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.6.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.6.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.6.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.7.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.7.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.7.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.7.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.8.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.8.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.8.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.8.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics
    • 5.9.3. Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics *
    • 5.9.4. Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics *
    • 5.9.5. Diagnosed Cases of the Acromegaly and Gigantism Therapeutics
    • 5.9.6. Treatable Cases of the Acromegaly and Gigantism Therapeutics

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Acromegaly and Gigantism Therapeutics

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Acromegaly and Gigantism Therapeutics

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Acromegaly and Gigantism Therapeutics : 7MM Market Analysis

  • 12.1. 7MM Market Size of Acromegaly and Gigantism Therapeutics
  • 12.2. 7MM Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics
  • 12.3. 7MM Market Sales of Acromegaly and Gigantism Therapeutics by Products

13. Acromegaly and Gigantism Therapeutics : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Acromegaly and Gigantism Therapeutics in United States
    • 13.1.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in United States
    • 13.1.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Acromegaly and Gigantism Therapeutics in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in Germany
      • 13.2.1.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Acromegaly and Gigantism Therapeutics in France
      • 13.2.2.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in France
      • 13.2.2.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Acromegaly and Gigantism Therapeutics in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in Italy
      • 13.2.3.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Acromegaly and Gigantism Therapeutics in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in Spain
      • 13.2.4.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Acromegaly and Gigantism Therapeutics in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in United Kingdom
      • 13.2.5.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Acromegaly and Gigantism Therapeutics in Japan
    • 13.3.2. Percentage Share of drugs marketed for Acromegaly and Gigantism Therapeutics in Japan
    • 13.3.3. Market Sales of Acromegaly and Gigantism Therapeutics by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Table 7: Treatable Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Table 12: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Table 16: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Table 17: Treatable Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Table 22: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Table 27: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Table 32: Treatable Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Table 37: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 42:7MM- Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 45: United States-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 48: Germany-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 51: France-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 54: Italy-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 57: Spain-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 60:UK-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Table 63: Japan-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Figure 7: Treatable Cases of the Acromegaly and Gigantism Therapeutics in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Figure 17: Treatable Cases of the Acromegaly and Gigantism Therapeutics in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Figure 32: Treatable Cases of the Acromegaly and Gigantism Therapeutics in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Acromegaly and Gigantism Therapeutics in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 45: United States-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 51: France-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 60:UK-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Acromegaly and Gigantism Therapeutics in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Acromegaly and Gigantism Therapeutics by Therapies in USD MM (2016-2028)